All News

Involving children in cancer caregiving may lessen fears and help with understanding.

Combining Fludara (fludarabine), Cytoxan (cyclophosphamide), and Rituxan (rituximab) was safer and produced a higher response than pairing Campath (alemtuzumab) with Fludara and Cytoxan in patients under age 65 with advanced B-cell chronic lymphocytic leukemia receiving their first treatment.

Treanda (bendamustine) may be an effective substitute for CHOP as the chemotherapy partner to Rituxan (rituximab) for patients receiving initial therapy for advanced follicular or mantle cell lymphomas.

The key findings from a phase 3 Spanish study are three-fold: less aggressive initial (induction) therapy with once-weekly—rather than twice-weekly—Velcade (bortezomib) was effective; melphalan outdid thalidomide as a partner to Velcade; and following induction with maintenance therapy may be the best approach for treating multiple myeloma patients over 65 who haven’t received previous treatment.

Vitamin supplementation can reduce certain side effects of Folotyn (pralatrexate), and the majority of patients are able to tolerate the full dose, concluded two safety studies in relapsed or refractory peripheral T-cell lymphoma.

Readers share how cancer was a positive experience for them and their family.

In the past, doctors advised breast cancer survivors with lymphedema to avoid heavy lifting because of the possibility of infection and symptom flare-ups, but a new study shows weight-lifting may actually be beneficial and help reduce lymphedema symptoms.

Two recent studies offer hope of enhancing both the effectiveness and safety of Herceptin, the drug that helped introduce the era of targeted therapy.